Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

Inal, Ali; Ciltas, Aydin; Yildiz, Ramazan; Berk, Veli; Kos, F. Tugba; Dane, Faysal; Unek, Ilkay Tugba; Colak, Dilsen; Ozdemir, Nuriye Yildirim; Buyukberber, Suleyman; Gumus, Mahmut; Ozkan, Metin; Isikdogan, Abdurrahman

추천

검색

자료유형: 학술저널

저자정보: Inal, Ali (Department of Medical Oncology, Dicle University) Ciltas, Aydin (Gazi University) Yildiz, Ramazan (Dr. Lutfi Kirdar Kartal Education and Research Hospital) Berk, Veli (Erciyes University) Kos, F. Tugba (Ankara Numune Education and Research Hospital) Dane, Faysal (Division of Medical Oncology, Marmara University School of Medicine) Unek, Ilkay Tugba (Department of Medical Oncology, Dokuz Eylul University) Colak, Dilsen (Yildirim Beyazit Education and Research Hospital) Ozdemir, Nuriye Yildirim (Ankara Numune Education and Research Hospital) Buyukberber, Suleyman (Gazi University) Gumus, Mahmut (Dr. Lutfi Kirdar Kartal Education and Research Hospital) Ozkan, Metin (Erciyes University) Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제5호

발행연도: 2012.1

수록면: 1,841 - 1,844 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy has limited impact on overall survival (OS) so that eligible patients should be selected carefully. The aim of this study was to analyze prognostic factors for survival in Turkish advanced pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving gemcitabine (Gem) alone or gemcitabine plus cisplatin (GemCis). Methods: This retrospective evaluation was performed for patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and who received gemcitabine between December 2005 and August 2011. Twenty-seven potential prognostic variables were chosen for univariate and multivariate analyses to identify prognostic factors associated with survival. Results: Among the 27 variables in univariate analysis, three were identified to have prognostic significance: sex (p = 0.04), peritoneal dissemination (p =0.02) and serum creatinine level (p=0.05). Multivariate analysis by Cox proportional hazard model showed only peritoneal dissemination to be an independent prognostic factor for survival. Conclusion: In conclusion, peritoneal metastasis was identified as an important prognostic factor in metastatic pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving Gem or GemCis. The findings should facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.

#Pancreas #cancer #gemcitabin #prognosis #long term survivors

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요